NASDAQ:KALV

KalVista Pharmaceuticals Stock Forecast, Price & News

$16.44

+0.31 (+1.92 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$15.79

Now: $16.44▼

$16.61

50-Day Range

$15.64

MA: $17.57▼

$19.28

52-Week Range

$5.61

Now: $16.44▼

$20.21

Volume45,990 shs

Average Volume129,219 shs

Market Capitalization$294.97 million

P/E RatioN/A

Dividend YieldN/A

Beta2.13

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.95 out of 5 stars

Medical Sector

68th out of 1,922 stocks

Pharmaceutical Preparations Industry

27th out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $31.33, KalVista Pharmaceuticals has a forecasted upside of 90.6% from its current price of $16.44.
Amount of Analyst Coverage
KalVista Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
KalVista Pharmaceuticals has received 294 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
KalVista Pharmaceuticals has received 206 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
KalVista Pharmaceuticals has received 58.80% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about KalVista Pharmaceuticals and other stocks. Vote “Outperform” if you believe KALV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
KalVista Pharmaceuticals does not currently pay a dividend.
Dividend Growth
KalVista Pharmaceuticals does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, KalVista Pharmaceuticals insiders have bought 2,181.95% more of their company's stock than they have sold. Specifically, they have bought $1,994,427.00 in company stock and sold $87,400.00 in company stock.
Percentage Held by Insiders
Only 18.00% of the stock of KalVista Pharmaceuticals is held by insiders.
Percentage Held by Institutions
90.19% of the stock of KalVista Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for KalVista Pharmaceuticals are expected to decrease in the coming year, from ($2.67) to ($3.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of KalVista Pharmaceuticals is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of KalVista Pharmaceuticals is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
KalVista Pharmaceuticals has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KALV

Previous Symbol

CUSIPN/A

CIK1348911

Webwww.kalvista.com

Phone857-999-0075

Employees56

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio7.56

Quick Ratio7.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$12.69 million

Price / Sales23.24

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.69 per share

Price / Book3.51

Profitability

EPS (Most Recent Fiscal Year)($1.64)

Net Income$-29,120,000.00

Net Margins-229.45%

Return on Equity-47.45%

Return on Assets-41.84%

Miscellaneous

Outstanding Shares17,942,000

Market Cap$294.97 million

Next Earnings Date3/9/2021 (Estimated)

OptionableNot Optionable

$16.44

+0.31 (+1.92 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

KalVista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

How has KalVista Pharmaceuticals' stock been impacted by COVID-19?

KalVista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KALV shares have increased by 85.6% and is now trading at $16.44.
View which stocks have been most impacted by COVID-19.

Is KalVista Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KalVista Pharmaceuticals stock.
View analyst ratings for KalVista Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than KalVista Pharmaceuticals?

Wall Street analysts have given KalVista Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but KalVista Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is KalVista Pharmaceuticals' next earnings date?

KalVista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for KalVista Pharmaceuticals.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its earnings results on Wednesday, December, 9th. The specialty pharmaceutical company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.09. KalVista Pharmaceuticals had a negative trailing twelve-month return on equity of 47.45% and a negative net margin of 229.45%.
View KalVista Pharmaceuticals' earnings history.

What price target have analysts set for KALV?

3 brokers have issued 1 year target prices for KalVista Pharmaceuticals' stock. Their forecasts range from $25.00 to $39.00. On average, they expect KalVista Pharmaceuticals' stock price to reach $31.33 in the next twelve months. This suggests a possible upside of 90.6% from the stock's current price.
View analysts' price targets for KalVista Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of KalVista Pharmaceuticals' key competitors?

Some companies that are related to KalVista Pharmaceuticals include Theravance Biopharma (TBPH), Phathom Pharmaceuticals (PHAT), Karyopharm Therapeutics (KPTI), Northwest Biotherapeutics (NWBO), Organogenesis (ORGO), Intercept Pharmaceuticals (ICPT), Zogenix (ZGNX), Akero Therapeutics (AKRO), Lexicon Pharmaceuticals (LXRX), ORIC Pharmaceuticals (ORIC), Humanigen (HGEN), Radius Health (RDUS), Morphic (MORF), Cara Therapeutics (CARA) and Annexon (ANNX).
View all of KALV's competitors.

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

Who are KalVista Pharmaceuticals' key executives?

KalVista Pharmaceuticals' management team includes the following people:

Mr. Thomas Andrew Crockett, CEO & Director (Age 46, Pay $568k)
Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 55, Pay $446.9k)
Mr. Christopher M. Yea Ph.D., Chief Devel. Officer (Age 57, Pay $445.27k)
Dr. Edward P. Feener, Chief Scientific Officer (Age 61)
Leah Monteiro, Director of Corp. Communications & Investor Relations
Ms. Rachel Morten, Head of Regulatory Affairs and QA
Mr. Andreas Maetzel, Sr. VP of Medical (Age 58)
Mr. Michael D. Smith Pharm.D., Sr. VP of Devel. (Age 42)
Mr. Stephen Donnelly, Director of Fin. and Company Sec.
Mr. John B. McKune, VP of Fin. (Age 45)

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KalVista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $16.44.

How big of a company is KalVista Pharmaceuticals?

KalVista Pharmaceuticals has a market capitalization of $294.97 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. KalVista Pharmaceuticals employs 56 workers across the globe.

What is KalVista Pharmaceuticals' official website?

The official website for KalVista Pharmaceuticals is www.kalvista.com.

How can I contact KalVista Pharmaceuticals?

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here